지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2012.1
- 수록면
- 68 - 75 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Cyclooxygenase (COX)-2 and matrix metalloproteinase (MMP)-9 play a key role in the pathogenesis of in-stent restenosis. We investigated the effect of a short-term therapy of celecoxib, a COX-2 inhibitor, with or without doxycycline, an MMP inhibitor, after coronary stenting on inflammatory biomarkers and neointimal hyperplasia. Materials and Methods: A total of 75 patients (86 lesions) treated with bare metal stents were randomized into three groups: 1) combination therapy (200 mg celecoxib and 20 mg doxycycline, both twice daily), 2) celecoxib (200 mg twice daily) only, and 3) non-therapy control. Celecoxib and doxycycline were administered for 3 weeks after coronary stenting. The primary endpoint was neointimal volume obstruction by intravascular ultrasound (IVUS) at 6 months. The secondary endpoints included clinical outcomes, angiographic data, and changes in blood levels of inflammatory biomarkers. Results: Follow-up IVUS revealed no significant difference in the neointimal volume obstruction among the three treatment groups. There was no difference in cardiac deaths, myocardial infarctions, target lesion revascularization or stent thrombosis among the groups. Blood levels of high-sensitivity C-reactive protein, soluble CD40 ligand, and MMP-9 varied widely 48 hours and 3 weeks after coronary stenting, however, they did not show any significant difference among the groups. Conclusion: Our study failed to demonstrate any beneficial effects of the short-term therapy with celecoxib and doxycycline or with celecoxib alone in the suppression of inflammatory biomarkers or in the inhibition of neointimal hyperplasia. Large scale randomized trials are necessary to define the role of anti-inflammatory therapy in the inhibition of neointimal hyperplasia.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Bendeck MP / 1996 / Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury / Circ Res 78 :
Bendeck MP / 2002 / Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury / Am J Pathol 160 : 1089 ~ 1095
Bogaty P / 2004 / Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-react
Bresalier RS / 2005 / Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial / N Engl J Med 352 : 1092 ~ 1102
Chenevard R / 2003 / Selective COX-2 inhibition improves endothelial function in coronary artery disease / Circulation 107 : 405 ~ 409
Bendeck MP / 2002 / Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury / Am J Pathol 160 : 1089 ~ 1095
Bogaty P / 2004 / Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-react
Bresalier RS / 2005 / Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial / N Engl J Med 352 : 1092 ~ 1102
Chenevard R / 2003 / Selective COX-2 inhibition improves endothelial function in coronary artery disease / Circulation 107 : 405 ~ 409
이 논문의 저자 정보
최근 본 자료
댓글(0)
0